Adoración Navarro-Torné
Research Subjects
Adoración Navarro-Torné has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Anja Anderson
Blood Safety, Hepatitis, STI and HIV Division, UK Health Security Agency , London
2 shared publications Bernd Benninghoff
A&N Immugen, Egloffstein 91349
2 shared publications- Emmanuelle Ghys
GSK, Wavre, Belgium
2 shared publications - Marta Checchi
Blood Safety, Hepatitis, Sexually Transmitted Infections (STI) and HIV Division, UK Health Security Agency, London, UK
2 shared publications - Simon Beddows
Virus Reference Department, Public Health Microbiology Division, UK Health Security Agency , London
2 shared publications - Vincent Weynants
GSK, Rixensart, Belgium
2 shared publications
Latest Publications
- Open Access
- 30 January 2026
- Published by Oxford University Press (OUP) in Journal of Public Health
- Vol. 48 (1) , 216-227
Maximizing impact: the power of early HPV vaccination for long-term protection―lessons from a systematic review and meta-regression analysis
Background: This systematic review and meta-regression analysis assessed the impact of human papillomavirus 16/18 (HPV16/18)-AS04 vaccine (Cervarix®) on advanced cervical lesions, including grade 3 cervical intraepithelial neoplasia or worse (CIN3, CIN3+), or cervical cancer, highlighting age-at-vaccination–dependent vaccine efficacy and effectiveness. Methods: Studies reporting HPV16/18-AS04 vaccine efficacy or effectiveness were included with an intervention group receiving HPV16/18-AS04 vaccine and comparator group receiving placebo, another vaccine or being unvaccinated. Of 53 articles identified, nine were selected. Meta-analysis and meta-regression models with random effects and data-driven model selection determined vaccine effects (VEs) and impactful covariates. Results: HPV16/18-AS04 vaccine effectively prevented advanced cervical premalignant lesions and cancer in adolescent girls and women vaccinated at 12–25 years. Combined randomized controlled trials and observational studies VEs on CIN3+ ranged between 76.78% (95% CI 28.15–92.49) for HPV16/18 and 56.19% (95% CI 24.76–74.49) irrespective of HPV type. Vaccine effectiveness was greatest in those vaccinated at the youngest ages. Conclusions: HPV16/18-AS04 vaccine provides long-term protection against cervical premalignant lesions and cervical cancer in both controlled and real-world settings, particularly when administered at younger ages. The evidence urges policymakers and the community to ensure HPV vaccination begins at the youngest recommended ages.
- 30 January 2026
- Published by Oxford University Press (OUP) in Journal of Public Health
- Vol. 48 (1) , 216-227
Open AccessMaximizing impact: the power of early HPV vaccination for long-term protection―lessons from a systematic review and meta-regression analysis
Background: This systematic review and meta-regression analysis assessed the impact of human papillomavirus 16/18 (HPV16/18)-AS04 vaccine (Cervarix®) on advanced cervical lesions, including grade 3 cervical intraepithelial neoplasia or worse (CIN3, CIN3+), or cervical cancer, highlighting age-at-vaccination–dependent vaccine efficacy and effectiveness. Methods: Studies reporting HPV16/18-AS04 vaccine efficacy or effectiveness were included with an intervention group receiving HPV16/18-AS04 vaccine and comparator group receiving placebo, another vaccine or being unvaccinated. Of 53 articles identified, nine were selected. Meta-analysis and meta-regression models with random effects and data-driven model selection determined vaccine effects (VEs) and impactful covariates. Results: HPV16/18-AS04 vaccine effectively prevented advanced cervical premalignant lesions and cancer in adolescent girls and women vaccinated at 12–25 years. Combined randomized controlled trials and observational studies VEs on CIN3+ ranged between 76.78% (95% CI 28.15–92.49) for HPV16/18 and 56.19% (95% CI 24.76–74.49) irrespective of HPV type. Vaccine effectiveness was greatest in those vaccinated at the youngest ages. Conclusions: HPV16/18-AS04 vaccine provides long-term protection against cervical premalignant lesions and cervical cancer in both controlled and real-world settings, particularly when administered at younger ages. The evidence urges policymakers and the community to ensure HPV vaccination begins at the youngest recommended ages.